Mga Batayang Estadistika
| LEI | 549300QKJ78IY0IOV655 |
| CIK | 1421876 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Galapagos NV - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 7, 2025 |
Galapagos Creates New Subscription Right Plan EdgarFiling EXHIBIT 99.1 Galapagos Creates New Subscription Right Plan Mechelen, Belgium; August 7, 2025, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,800,000 subscription rights under a new subscription right plan. On August 7, 2025, the Board of Directors of Galapagos approved “Subscription Right Plan 2025 (B)”, i |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive of |
|
| August 6, 2025 |
EXHIBIT 99.1 Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma Mechelen, Belgium; August 6, 2025, 7:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the United States Food and Drug Administration (FDA) has granted |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive of |
|
| July 24, 2025 |
EX-99.2 Exhibit 99.2 ABOUT THIS REPORT About This Report This report contains information required under Belgian law. Galapagos NV is a limited liability company organized under the laws of Belgium, having its registered office at Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium and registered with the Crossroads Enterprise Database (RPR Antwerp – division Mechelen) under number 0466.460.429. |
|
| July 24, 2025 |
EX-99.1 Exhibit 99.1 Galapagos Reports Half-Year 2025 Financial Results and Provides Second Quarter Business Update Appointments of new CEO, CFO, and seasoned business development leaders with proven track records of executing strategic transactions will position the Company to drive shareholder value and advance pipeline expansion Strategic alternatives for the cell therapy business, including a |
|
| July 24, 2025 |
EXHIBIT 99.1 Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Accelerate Business Transformation Appoints Sooin Kwon as Chief Business Officer and Dan Grossman as Chief Strategy Officer Both executives possess proven track records in strategic execution and deal-making and will help drive long-term value creation at Galapagos Mechelen, Belgium; July 23, 2025, 22.01 CET; |
|
| July 24, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant’s name into English) Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium (Address of principal executive |
|
| July 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive offi |
|
| July 23, 2025 |
EXHIBIT 99.1 Galapagos Welcomes Seasoned Pharmaceutical Executives Dawn Svoronos and Jane Griffiths to Its Board of Directors New Directors bring deep commercial, operational, and transaction experience to the Board Mechelen, Belgium; July 23, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointments by way of co-optation of Dawn Svoronos and Jane Griffiths as Non-Ex |
|
| July 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive offi |
|
| June 25, 2025 |
Galapagos Appoints Aaron Cox as Chief Financial Officer EXHIBIT 99.1 Galapagos Appoints Aaron Cox as Chief Financial Officer Former Horizon CFO joins Galapagos with deep expertise in international corporate finance, M&A, business development and strategic leadership Mechelen, Belgium; June 23, 2025, 07:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointment of Mr. Aaron Cox as Chief Fi |
|
| June 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive offi |
|
| June 20, 2025 |
EdgarFiling EXHIBIT 99.1 Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101 Of the 34 patients enrolled in Cohort 3 of the ATALANTA-1 Phase 1/2 study, 32 received GLPG5101; 94% were infused with fresh CAR-T cells, and 93% were treated within s |
|
| June 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive offi |
|
| June 13, 2025 |
EXHIBIT 99.1 Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL Data reported from the ongoing ATALANTA-1 Phase 1/2 study in a heavily pretreated relapsed refractory non-Hodgkin’s Lymphoma (R/R NHL) patient population demonstrate low rates of high-grade toxicities Of the 64 pati |
|
| June 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive offi |
|
| May 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive offic |
|
| May 28, 2025 |
Galapagos Creates New Subscription Right Plan EXHIBIT 99.1 Galapagos Creates New Subscription Right Plan Mechelen, Belgium; May 27, 2025, 22:30 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 925,000 subscription rights under a new subscription right plan. On May 27, 2025, the Board of Directors of Galapagos approved “Subscription Right Plan 2025 (A)”, intended for person |
|
| May 14, 2025 |
EXHIBIT 99.1 Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101 Mechelen, Belgium; May 14, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today announced that new dat |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive offic |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive offic |
|
| May 13, 2025 |
EdgarFiling EXHIBIT 99.1 Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes Galapagos to re-evaluate the implementation of the previously announced separation following regulatory and market developments Galapagos to explore all strategic alternatives for its existing businesses, including cell therapy, with a focus on maximizing resource |
|
| April 29, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025. Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant’s name into English) Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium (Address of principal executi |
|
| April 23, 2025 |
EXHIBIT 99.1 Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts First U.S. patient dosed in ATALANTA-1 study of GLPG5101 Mantle cell lymphoma (MCL), a high-unmet-need hematological malignancy, selected as lead indication for the GLPG5101 program; Pivotal development planned to start in 2026 and aiming for approval in 2028 Executive leadership |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive off |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive off |
|
| April 21, 2025 |
EXHIBIT 99.1 Galapagos Announces Executive Leadership Updates Mr. Henry Gosebruch appointed by the Galapagos Board of Directors as founding CEO of newly created SpinCo Dr. Paul Stoffels, Chair and CEO of Galapagos, plans to retire as CEO upon appointment of successor in the next 12 months and plans to continue as Chair of the Board of Directors, ensuring leadership continuity and long-term strateg |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive off |
|
| April 15, 2025 |
Galapagos Announces Departure of Thad Huston, CFO and COO, as of August 1, 2025 EXHIBIT 99.1 Galapagos Announces Departure of Thad Huston, CFO and COO, as of August 1, 2025 Mechelen, Belgium; April 15, 2025, 07:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today announced the departure of its CFO and COO, Thad H |
|
| March 28, 2025 |
EX-99.10 Exhibit 99.10 GALAPAGOS Naamloze Vennootschap / Limited Liability Company Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium RPR / RLE Antwerp, division Mechelen 0466.460.429 Op 27 maart 2025 bedraagt het totaal aantal aandelen en stemrechten van Galapagos NV 65.897.071 On March 27, 2025, the total number of shares and voting rights of Galapagos NV amounts to 65,897,071 |
|
| March 28, 2025 |
Exhibit 99.5 F-cap 1 ANNUAL ACCOUNTS AND OTHER DOCUMENTS TO BE FILED IN ACCORDANCE WITH THE BELGIAN COMPANIES AND ASSOCIATIONS CODE IDENTIFICATION DETAILS (at the filing date) NAME: Galapagos Legal form 1 : Public limited company Address: Generaal De Wittelaan Postal code: 2800 Town: Mechelen N°. L11 , box A3 Country: Belgium Register of legal persons - commercial court: Antwerp, division Mechelen |
|
| March 28, 2025 |
Exhibit 99.7 Time Sensitive Materials Depositary’s Notice of Shareholders’ Meeting of Galapagos NV ADSs: American Depositary Shares (“ADSs”). ADS CUSIP No.: 36315X101. Company: Galapagos NV, a company organized and existing under the laws of the Kingdom of Belgium (the “Company”). ADS Record Date: March 24, 2025 (5:00 P.M. New York City time). Date used to determine ADS Holders who are to receive |
|
| March 28, 2025 |
Exhibit 99.9 Gewone Algemene Vergadering van 29 april 2025 Annual Shareholders’ Meeting of April 29, 2025 Kennisgeving van deelname Notification of participation (enkel te gebruiken door houders van aandelen op naam of inschrijvingsrechten, die geregistreerd werden op 15 april 2025) (to be used by holders of registered shares or subscription rights only, registered on 15 April 2025) De ondergetek |
|
| March 28, 2025 |
Exhibit 99.3 Free translation from Dutch For information purposes only GALAPAGOS NV Limited liability company Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium Company Number: 0466.460.429 RLE Antwerp - division Mechelen Invitation to the Annual Shareholders’ Meeting to be held on April 29, 2025 The Board of Directors of Galapagos NV (hereinafter the “Company”, or “Galapagos”) has the hono |
|
| March 28, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025. Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant’s name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executiv |
|
| March 28, 2025 |
Pioneering scienceto transform patient outcomesAnnual Report 2024 Exhibit 99.2 Pioneering scienceto transform patient outcomesAnnual Report 2024 ABOUT THIS REPORT About this ReportThis report contains information required under Belgian law. Galapagos NV is a limited liability company organized under the laws of Belgium, with itsregistered office at Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium and registered with the Crossroads Enterprise Database (RPR An |
|
| March 28, 2025 |
Galapagos Publishes 2024 Annual Report and Announces Annual Shareholders’ Meeting EX-99.1 Exhibit 99.1 Galapagos Publishes 2024 Annual Report and Announces Annual Shareholders’ Meeting Mechelen, Belgium; March 27, 2025, 21:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today publishes its annual report for the financial year 2024 and announces its Annual Shareholders’ Meeting (AGM) to be held on Tuesday, April 29, 2025 at 14:00 CET at the registered offi |
|
| March 28, 2025 |
Exhibit 99.6 T: +32 (0)2 778 01 00 www.bdo.be The Corporate Village Da Vincilaan 9, Box E.6 Elsinore Building B-1930 Zaventem GALAPAGOS NV Statutory auditor’s report to the general meeting for the year ended 31 December 2024 Free translation BDO Bedrijfsrevisoren BV / BTW BE 0431.088.289 / RPR Brussel BDO Réviseurs d’Entreprises SRL / TVA BE 0431.088.289 / RPM Bruxelles BDO Bedrijfsrevisoren - BDO |
|
| March 28, 2025 |
Volmacht (enkel te gebruiken door aandeelhouders) Exhibit 99.4 Gewone Algemene Vergadering van 29 april 2025; Annual Shareholders’ Meeting of April 29, 2025; Volmacht (enkel te gebruiken door aandeelhouders) Proxy (to be used by shareholders only) De ondergetekende: The undersigned: (Naam en adres / Name and address) hierin optredend als lastgever, eigenaar van het volgende aantal aandelen in Galapagos NV (naamloze vennootschap naar Belgisch re |
|
| March 28, 2025 |
Stemmen per brief (enkel te gebruiken door aandeelhouders) Exhibit 99.11 Gewone Algemene Vergadering van 29 april 2025; Annual Shareholders’ Meeting of April 29, 2025; Stemmen per brief (enkel te gebruiken door aandeelhouders) Voting by letter (to be used by shareholders only) De ondergetekende: The undersigned: (Naam en adres / Name and address) eigenaar van het volgende aantal aandelen in Galapagos NV (naamloze vennootschap naar Belgisch recht, met zet |
|
| March 28, 2025 |
Exhibit 99.8 Annual Shareholders’ Meeting The Voting Instructions must be signed, completed and received at the indicated address prior to 10:00 A.M. (New York City time) on April 21, 2025 for action to be taken. 2025 VOTING INSTRUCTIONS AMERICAN DEPOSITARY SHARES Galapagos NV (the “Company”) ADS CUSIP No.: 36315X101. ADS Record Date: March 24, 2025 (5:00 P.M. New York time). Share Record Date: Ap |
|
| March 27, 2025 |
Restricted Stock Units/Exceptional Plan 2024 – Participants’ Guide Exhibit 4.67 Confidential RSU/Exceptional 2024 Restricted Stock Units/Exceptional Plan 2024 – Participants’ Guide This multi-year Plan is intended to provide certain members of the personnel of Galapagos or its Affiliates and certain legal or natural persons providing services to Galapagos or an Affiliate the opportunity to receive Restricted Stock Units as a long-term incentive. Its purpose is to |
|
| March 27, 2025 |
Consent of Independent Registered Public Accounting Firm EXHIBIT 15.2 Consent of Independent Registered Public Accounting Firm We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-204567, 333-208697, 333-211834, 333-215783, 333-218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, 333-275886 and 333-283361) of Galapagos NV of our reports dated March 27, 2025, relating to the consolidated f |
|
| March 27, 2025 |
Exhibit 2.3 DESCRIPTION OF SECURITIES The following description of the securities registered under Section 12 of the Securities Exchange Act of 1934 of Galapagos NV (“Galapagos,” “us,” “our,” “we” or the “Company”) is a summary of the rights of our ordinary shares and certain provisions of our Articles of Association in effect as of April 30, 2024. This summary does not purport to be complete and |
|
| March 27, 2025 |
Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Thad Huston, certify that: 1. I have reviewed this annual report on Form 20-F of Galapagos NV; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to |
|
| March 27, 2025 |
COMPENSATION RECOVERY POLICY Adopted as of September 19, 2023 Exhibit 97.1 COMPENSATION RECOVERY POLICY Adopted as of September 19, 2023 Galapagos NV, a limited liability company incorporated in Belgium (the “Company”), acting on its own behalf and on behalf of its subsidiaries with whom Executive Officers as defined below have entered into service agreements regarding their Executive Officer role, has adopted a Compensation Recovery Policy (this “Policy”) a |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
|
| March 27, 2025 |
Exhibit 1.1 Free translation from Dutch For information purposes only GALAPAGOS Limited Liability Company With office at Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium Judicial district of Mechelen (Belgium) Registered with the Register of Legal Entities under number 0466.460.429 www.glpg.com ********************* Coordination of the Articles of Association per 30 April 2024 **************** |
|
| March 27, 2025 |
Exhibit 13.1 Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the annual report of Galapagos NV (the “Company”) on Form 20-F for the fiscal year ended December 31, 2024 as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), I, Stoffels IM |
|
| March 27, 2025 |
Restricted Stock Units/Long-Term Incentive Plan 2024 – Participants’ Guide Exhibit 4.66 Confidential RSU/LTIP 2024 Restricted Stock Units/Long-Term Incentive Plan 2024 – Participants’ Guide This multi-year Plan is intended to provide certain members of the Executive Committee, certain employees of Galapagos or its Affiliates and certain legal or natural persons providing services to Galapagos or an Affiliate the opportunity to receive Restricted Stock Units as a long-ter |
|
| March 27, 2025 |
Exhibit 4.69 Execution Version TRANSFER AGREEMENT This Transfer Agreement (“Agreement”) is entered into as of January 7, 2025 and effective as of such date (the “Execution Date”) by and between GALAPAGOS NV, a corporation organized under the laws of Belgium and having its principal place of business at Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium (“Galapagos”) and GILEAD SCIENCES, INC., a |
|
| March 27, 2025 |
Exhibit 13.2 Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the annual report of Galapagos NV (the “Company”) on Form 20-F for the fiscal year ended December 31, 2024 as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), I, Thad Huston |
|
| March 27, 2025 |
Exhibit 4.68 Remuneration Policy This revised Remuneration Policy (‘Remuneration Policy’) of Galapagos NV (‘Galapagos’) is established in accordance with Article 7:89/1 of the Belgian Code of Companies and Associations and the 2020 Belgian Code of Corporate Governance (‘2020 Code’) and is applicable to Galapagos’ non-executive Directors and Executive Committee members. The Remuneration Policy was |
|
| March 27, 2025 |
Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Stoffels IMC BV, permanently represented by Dr. Paul Stoffels, certify that: 1. I have reviewed this annual report on Form 20-F of Galapagos NV; 2. Based on my knowledge, this report does not contain |
|
| March 27, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement Nos. 333-283361, 333-275886, 333-268756, 333-260500, 333-249416, 333-231765, 333-225263, 333-218160, 333-215783, 333-211834, 333-208697 and 333-204567, on Form S-8 of our report dated March 23, 2023 (March 28, 2024 as to the effects of the discontinued operat |
|
| March 27, 2025 |
Exhibit 11.1 Galapagos Dealing Code This Dealing Code has last been updated on 5 May 2023 pursuant to the power of attorney granted to the General Counsel of Galapagos NV by the Board of Directors of Galapagos NV of 9 December 2022. 1Introduction Galapagos NV is a publicly listed limited liability company (“naamloze vennootschap”/”société anonyme”), organized under the laws of Belgium, having its |
|
| February 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive |
|
| February 24, 2025 |
Galapagos to Present at Upcoming Investor Conferences EdgarFiling EXHIBIT 99.1 Galapagos to Present at Upcoming Investor Conferences Mechelen, Belgium; February 24, 2025, 22:01 CET – Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today announced that its management will present at the following investor conferences in March: TD Cowen 45th |
|
| February 18, 2025 |
Galapagos receives transparency notification and 13D filing from Tang Capital EdgarFiling EXHIBIT 99.1 Galapagos receives transparency notification and 13D filing from Tang Capital Mechelen, Belgium; February 17, 2025, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification and 13D filing from Tang Capital. Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on February 14, 2025 |
|
| February 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive |
|
| February 14, 2025 |
Schedule A Transactions during the past 60 days EX-99.2 3 ex992.htm EXHIBIT 99.2 EXHIBIT 2 Schedule A Transactions during the past 60 days Transaction Date Nature of Transaction Quantity Security Type* Weighted Average Price Per Share** Price Range Min Max 12/16/2024 Purchase 9,441 Ordinary Shares € 25.17 € 24.92 € 25.40 12/16/2024 Purchase 47,176 ADRs $26.84 $26.50 $27.00 12/17/2024 Purchase 2,989 Ordinary Shares € 25.30 € 25.16 € 25.40 12/17/ |
|
| February 14, 2025 |
EX-99.1 2 ex991.htm EXHIBIT 99.1 EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13D referred to below) on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with resp |
|
| February 12, 2025 |
Exhibit 99.2 Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein Focusing on accelerating GLPG5101 program, expanding to eight indications with significant unmet needs |
|
| February 12, 2025 |
Exhibit 99.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. SEPARATION AGREEMENT dated 7 January 2025 by and between GALAPAGOS NV Company and GILEAD THERAPEUTICS A1 UNLIMITED COMPANY Inve |
|
| February 12, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant’s name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal execut |
|
| January 10, 2025 |
Directors and Executive Officers of Gilead Exhibit 99.3 Directors and Executive Officers of Gilead All addresses are c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California, 94404. Name Title Citizenship Principal Occupation Daniel P. O’Day Chief Executive Officer, Chairman and Director United States * Jacqueline K. Barton, Ph.D. Director United States Professor Emerita, California Institute of Technology Jeffrey A. Blueston |
|
| January 10, 2025 |
Exhibit 99.4 Private and Confidential Execution copy CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND REPLACED WITH “[…***…]” BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SEPARATION AGREEMENT dated 7 January 2025 by and between GALAPAGOS NV Company and GILEAD THERAPEUTICS A1 UNLIMITED COMPANY Investor and GILEAD SCIENCES INC |
|
| January 8, 2025 |
Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference EXHIBIT 99.1 Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference Mechelen, Belgium; January 7, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 1:30 pm PT in San Francisco. A live webcast of the presentation will be accessible on the Inv |
|
| January 8, 2025 |
EXHIBIT 99.1 Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities Galapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a pipeline of innovative medicines through transformational transactions Galapagos will gain full global development and commercialization rights to its pipeline, focusing on |
|
| January 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive o |
|
| January 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive o |
|
| December 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive |
|
| December 9, 2024 |
EXHIBIT 99.1 Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma Data from the ongoing Phase 1/2 ATALANTA-1 study in a heavily pretreated R/R NHL patient population demonstrate high antitumor activity and an encouraging safety profile in all NHL subtypes studied. 96% of patients rec |
|
| November 20, 2024 |
Subscription Right Plan 2024 BE GALAPAGOS NV General Rules Exhibit 99.2 Free translation for information purposes only Subscription Right Plan 2024 BE GALAPAGOS NV General Rules Free translation for information purposes only Table of Contents 1 Basis and Purpose 3 2 Definitions 3 3 Subscription Rights 5 3.1 General 5 3.2 Number per Beneficiary 5 3.3 Transfer restrictions 5 3.4 Exercise Price 5 3.5 Administration of the Subscription Right Pla |
|
| November 20, 2024 |
Subscription Right Plan 2024 RMV GALAPAGOS NV General Rules Exhibit 99.3 Free translation for information purposes only Subscription Right Plan 2024 RMV GALAPAGOS NV General Rules Free translation for information purposes only Table of Contents 1 Basis and Purpose 4 2 Definitions 4 3 Subscription Rights 6 3.1 General 6 3.2 Number per Beneficiary 6 3.3 Transfer restrictions 6 3.4 Exercise Price 6 3.5 Administration of the Subscription Right Pl |
|
| November 20, 2024 |
Exhibit 4.1 Free translation from Dutch For information purposes only GALAPAGOS Limited Liability Company With office at Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium Judicial district of Mechelen (Belgium) Registered with the Register of Legal Entities under number 0466.460.429 www.glpg.com ********************* Coordination of the Articles of Association per 30 April 2024 **************** |
|
| November 20, 2024 |
As filed with the U.S. Securities and Exchange Commission on November 20, 2024 S-8 As filed with the U.S. Securities and Exchange Commission on November 20, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GALAPAGOS NV (Exact name of registrant as specified in its charter) Belgium Not applicable (State or other jurisdiction of incorporation or organization) (I |
|
| November 20, 2024 |
Subscription Right Plan 2024 ROW GALAPAGOS NV General Rules Exhibit 99.1 Free translation for information purposes only Subscription Right Plan 2024 ROW GALAPAGOS NV General Rules Free translation for information purposes only Table of Contents 1 Basis and Purpose 3 2 Definitions 3 3 Subscription Rights 5 3.1 General 5 3.2 Number per Beneficiary 5 3.3 Transfer restrictions 5 3.4 Exercise Price 5 3.5 Administration of the Subscription Right Plan 6 3.6 Expir |
|
| November 20, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Galapagos NV (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title (1) Fee Calculation Rule (2) Amount Registered (3) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price (2) Fee Rate Amount of Registration Fee Equity Ordinary Shares, no par value Other 1,614,000 $29. |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive |
|
| November 6, 2024 |
Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024 EXHIBIT 99.1 Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024 New Phase 1/2 data support the potential of our CAR T-cell therapy candidates, GLPG5101 and GLPG5201, in addressing unmet needs for patients with poor prognoses. Our innovative decentralized cell therapy manufacturing platform delivers fresh, fit cells within a median vein-to-vein time of seven da |
|
| October 31, 2024 |
Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update EXHIBIT 99.1 Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update We are advancing our pipeline and accelerating innovation through focused execution of our Forward, Faster strategy. We are committed to addressing the high unmet needs of patients through a growing cell therapy and small molecule pipeline with breakthrough potential. This includes more than 20 program |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive o |
|
| October 8, 2024 |
EX-99.2 2 tm2425722d1ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 TRADING DATA Entity Trade Date Type Quantity Name of Security Average Price per Share Description EcoR1 Capital Fund, L.P. 9/9/2024 Purchase 2,955 ADS $ 28.3122 Open Market transaction on NASDAQ EcoR1 Capital Fund, L.P. 9/10/2024 Purchase 3,995 ADS $ 28.7417 Open Market transaction on NASDAQ EcoR1 Capital Fund, L.P. 9/11/2024 Purchase 1,141 |
|
| October 8, 2024 |
SC 13D/A 1 tm2425722d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 1)* (Rule 13d-101) Information to be included in statements filed pursuant to § 240.13d-1(a) and amendments thereto filed pursuant to § 240.13d-2(a) Under the Securities Exchange Act of 1934 Galapagos NV (Name of Issuer) Ordinary Shares, no par value (Titl |
|
| October 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive o |
|
| October 7, 2024 |
Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth EXHIBIT 99.1 Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth Mechelen, Belgium; October 7, 2024, 07:00 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced the appointment by way of co-optation of Oleg Nodelman as Non-Executive Non-Independent Director to its Board of Directors, effective October 7, 2024. Mr. Nodelman replaces Mr. Dan G. Baker who st |
|
| September 30, 2024 |
Galapagos receives transparency notification from EcoR1 Capital EXHIBIT 99.1 Galapagos receives transparency notification from EcoR1 Capital Mechelen, Belgium; 30 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from EcoR1 Capital LLC. Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 26 September 2024 on behalf of Mr. Oleg Nodelman and |
|
| September 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive |
|
| September 16, 2024 |
Galapagos receives transparency notification from EcoR1 Capital EXHIBIT 99.1 Galapagos receives transparency notification from EcoR1 Capital Mechelen, Belgium; 16 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from EcoR1 Capital LLC. Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 13 September 2024 on behalf of Mr. Oleg Nodelman and |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive |
|
| September 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive |
|
| September 3, 2024 |
Galapagos receives transparency notification from FMR LLC EXHIBIT 99.1 Galapagos receives transparency notification from FMR LLC Mechelen, Belgium; 3 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC. Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 30 August 2024 from FMR LLC, who notified that it holds 2,687,116 of G |
|
| August 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Galapagos NV (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) 36315X101 (CUSIP Number) Oleg Nodelman EcoR1 Capital, LLC 357 Tehama Street #3 San Fransisco, CA 94103 (415) 448-6534 with a copy to Richard M. Brand Erica L. Hogan Cadwalader, Wicke |
|
| August 23, 2024 |
AGREEMENT JOINT FILING OF SCHEDULE 13D Exhibit 99.1 AGREEMENT JOINT FILING OF SCHEDULE 13D The undersigned hereby agree to jointly prepare and file with regulatory authorities this Schedule 13D and any future amendments thereto reporting each of the undersigned’s ownership of securities of Galapagos NV, and hereby affirm that such Schedule 13D is being filed on behalf of each of the undersigned pursuant to and in accordance with the pr |
|
| August 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive of |
|
| August 23, 2024 |
EXHIBIT 99.1 Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma Mechelen, Belgium; August 23, 2024, 07:00 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the U.S. Food and Drug Administration (FDA) has cleared Galapagos’ Investigational |
|
| August 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive of |
|
| August 21, 2024 |
Galapagos receives transparency notification from FMR LLC EXHIBIT 99.1 Galapagos receives transparency notification from FMR LLC Mechelen, Belgium; 20 August 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC. Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 16 August 2024 from FMR LLC, who notified that it holds 3,696,750 of Gal |
|
| August 2, 2024 |
Galapagos reports half-year 2024 financial results and provides second quarter business update Exhibit ex99.1 Galapagos reports half-year 2024 financial results and provides second quarter business update • Executing on our Forward, Faster strategy with strong progress in a pivotal year, focused on delivering regulatory and clinical milestones, expanding our cell therapy manufacturing capabilities, and advancing our early-stage programs. • Submitted IND application to FDA for our Phase 1/2 |
|
| August 2, 2024 |
Exhibit 99.2 Pioneering science to transform patient outcomes Half-year financial report 2024 Galapagos Pioneering for patients TABLE OF CONTENTS Table of Contents Management report Main events in the first six months of 2024 4 Financial highlights 8 The Galapagos share 14 Related party transactions 14 Risk factors 15 Disclaimer and other information 16 Financial statements Unaudited condensed con |
|
| August 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant’s name into English) Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium (Address of principal executive o |
|
| June 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive offi |
|
| June 17, 2024 |
EdgarFiling EXHIBIT 99.1 Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024 Mechelen, Belgium; June 14, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present encouraging new data from the ongoing Phase 1/2 ATALANTA-1 study of CD19 CAR-T candidate, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma |
|
| May 30, 2024 |
EXHIBIT 99.1 Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next generation MAGE-A4 TCR T-cell therapy) prod |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive offic |
|
| May 16, 2024 |
EXHIBIT 99.1 Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S. BCA's national network of blood centers will provide decentralized manufacturing services for Galapagos' CAR-T product candidates, close to cancer treatment centers Collaboration enables rapid deployment of Galapagos' decentralized CAR- |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive offic |
|
| May 16, 2024 |
Galapagos creates new subscription right plans EXHIBIT 99.1 Galapagos creates new subscription right plans Mechelen, Belgium; 16 May 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,614,000 subscription rights under new subscription right plans for the benefit of certain members of the personnel of the company and its subsidiaries. On 16 May 2024, the Board of |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive offic |
|
| May 3, 2024 |
Galapagos reports first quarter 2024 financial results EXHIBIT 99.1 Galapagos reports first quarter 2024 financial results Advanced potentially best-in-class cell therapy and small molecule R&D pipeline comprising four clinical assets and >15 discovery programs in oncology and immunology Executed agreements with BridGene Biosciences and Thermo Fisher Scientific, and investment in Frontier Medicines Transferred Jyseleca® business to Alfasigma S.p.A., f |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive offic |
|
| May 2, 2024 |
AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D EX-99.1 2 d829072dex991.htm EX-99.1 Exhibit 99.1 AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D The undersigned hereby agree to the joint filing on behalf of each of them of Amendment No. 3 to the Schedule 13D (including any and all further amendments thereto) with respect to the Ordinary Shares of Galapagos NV and further agree that this Joint Filing Agreement shall be included as an Exhibi |
|
| May 2, 2024 |
SC 13D/A 1 d829072dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* GALAPAGOS NV (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) 36315X101 (CUSIP Number) Gilead Sciences, Inc. 333 Lakeside Drive Foster City, California, 94404 650-574-3000 (Name, Address and Telephone |
|
| May 2, 2024 |
SUBSEQUENT GILEAD WARRANT B – issued by – GALAPAGOS NV – dated – [date] 2024 EX-99.2 3 d829072dex992.htm EX-99.2 Exhibit 99.2 SUBSEQUENT GILEAD WARRANT B – issued by – GALAPAGOS NV – dated – [date] 2024 TABLE OF CONTENT Articles Page 1. Certain Definitions and Interpretation 1 1.1. Certain definitions 1 1.2. Headings 3 1.3. Meaning of references 4 1.4. Fractional value of Shares 4 1.5. Language 4 2. Issuance, Nature and Form of the Warrant 5 2.1. Issuance and nature |
|
| May 1, 2024 |
EXHIBIT 99.1 Galapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024 Mechelen, Belgium; 30 April 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announces that all resolutions proposed at the company’s Annual and Extraordinary Shareholders’ Meetings (AGM and EGM) held on 30 April 2024 were approved. T |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive off |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024. Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant’s name into English) Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium (Address of principal executive off |
|
| April 8, 2024 |
EXHIBIT 99.1 Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024 Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) / Richter transformation (RT) Mechelen, Belgium; 4 April 2024, 22:01 CET – Ga |
|
| April 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive off |
|
| March 29, 2024 |
Exhibit 99.6 Phone: +32 (0)2 778 01 00 www.bdo.be The Corporate Village Da Vincilaan 9, Box E.6 Elsinore Building B-1930 Zaventem GALAPAGOS NV Statutory auditor’s report to the general meeting for the year ended 31 December 2023 Free translation BDO Bedrijfsrevisoren BV / BTW BE 0431.088.289 / RPR Brussel BDO Réviseurs d’Entreprises SRL / TVA BE 0431.088.289 / RPM Bruxelles BDO Bedrijfsrevisoren - |
|
| March 29, 2024 |
Exhibit 99.3 Free translation from Dutch For information purposes only GALAPAGOS NV Limited liability company Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium Company Number: 0466.460.429 RLE Antwerp - division Mechelen Invitation to the Annual and Extraordinary Shareholders’ Meetings to be held on 30 April 2024 The Board of Directors of Galapagos NV (hereinafter the “Company”, or “Galapagos”) |
|
| March 29, 2024 |
Pioneering science patient to transform outcomes Annual Report 2023 Exhibit 99.2 Pioneering science patient to transform outcomes Annual Report 2023 TABLE OF CONTENTS Table of Contents Our Business Disclaimer and other information 4 Our Company 7 Key achievements in 2023 15 Outlook 2024 27 Going concern statement 27 Risk management and internal control 28 Portfolio Portfolio 31 Oncology 32 Immunology 50 Risk factors Detailed description of the risk factors in Form |
|
| March 29, 2024 |
Exhibit 99.8 Phone : +32 (0)2 778 01 00 www.bdo.be The Corporate Village Da Vincilaan 9, Box E.6 Elsinore Building B-1930 Zaventem GALAPAGOS NV Report addressed to the general meeting concerning the financial and accounting data included in the report of the administrative body in accordance with of articles 7:180 CCA (issuance of subscription rights) and 7:191 (cancellation of the preferential su |
|
| March 29, 2024 |
Exhibit 99.13 GALAPAGOS Naamloze Vennootschap / Limited Liability Company Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium RPR / RLE Antwerp, division Mechelen 0466.460.429 Op 28 maart 2024 bedraagt het totaal aantal aandelen en stemrechten van Galapagos NV 65.897.071 On 28 March 2024, the total number of shares and voting rights of Galapagos NV amounts to 65,897,071 |
|
| March 29, 2024 |
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board EXHIBIT 99.1 Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board Mechelen, Belgium; 26 March 2024, 21:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that during its meeting of 26 March 2024, the Board of Directors appointed Mr. Dickinson as Non-Executive Non-Independent Director by way of cooptation. Andrew Dickinson is Gilead's Chief Financia |
|
| March 29, 2024 |
Exhibit 99.14 Gewone en Buitengewone Algemene Vergaderingen van 30 april 2024 Annual and Extraordinary Shareholders’ Meetings of 30 April 2024 Galapagos NV | Formulier stemmen per brief JAV/BAV 30 april 2024 | Voting by letter form AGM/EGM 30 April 2024 P. 1 | 13 Stemmen per brief (enkel te gebruiken door aandeelhouders) Voting by letter (to be used by shareholders only) De ondergetekende: The und |
|
| March 29, 2024 |
English translation for information purposes Exhibit 99.7 GALAPAGOS Limited Liability Company Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium Company number: 0466.460.429 RLE Antwerp, division Mechelen (the “Company”) Report of the Board of Directors in accordance with Articles 7:180, 7:191 and 7:193 of the Belgian Companies and Associations Code Cancellation of the preferential subs |
|
| March 29, 2024 |
Exhibit 99.10 Time Sensitive Materials Depositary’s Notice of Shareholders’ Meetings’ of Galapagos NV ADSs: American Depositary Shares (“ADSs”). ADS CUSIP No.: 36315X101. Company: Galapagos NV, a company organized and existing under the laws of the Kingdom of Belgium (the “Company”). ADS Record Date: March 25, 2024 (close of business in New York). Date used to determine ADS Holders who are to rece |
|
| March 29, 2024 |
Exhibit 99.4 Gewone en Buitengewone Algemene Vergaderingen van 30 april 2024 Annual and Extraordinary Shareholders’ Meetings of 30 April 2024 Volmacht Proxy (enkel te gebruiken door aandeelhouders) (to be used by shareholders only) De ondergetekende: The undersigned: (Naam en adres / Name and address) hierin optredend als lastgever, herein acting as grantor of a proxy, eigenaar van het volgende aa |
|
| March 29, 2024 |
Exhibit 99.5 F-cap 1 ANNUAL ACCOUNTS AND OTHER DOCUMENTS TO BE FILED IN ACCORDANCE WITH THE BELGIAN COMPANIES AND ASSOCIATIONS CODE IDENTIFICATION DETAILS (at the filing date) NAME: Galapagos Legal form 1: Public limited company Address: Generaal De Wittelaan Postal code: 2800 Town: Mechelen N°. L11 , box A3 Country: Belgium Register of legal persons - commercial court: Antwerp, division Mechelen |
|
| March 29, 2024 |
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings Exhibit 99.1 Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings • Publication of annual report for financial year 2023 • Annual Shareholders’ Meeting resolutions include approval of revised Remuneration Policy and (re)appointment of Board members • Extraordinary Shareholders’ Meeting resolutions include approval of renewal of authorized capital and |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024. Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant’s name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive of |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive off |
|
| March 29, 2024 |
Exhibit 99.11 Annual and Extraordinary Shareholders’ Meetings The Voting Instructions must be signed, completed and received at the indicated address prior to 10:00 A.M. (New York City time) on April 22, 2024 for action to be taken. 2024 VOTING INSTRUCTIONS AMERICAN DEPOSITARY SHARES Galapagos NV (the “Company”) ADS CUSIP No.: 36315X101. ADS Record Date: March 25, 2024 (close of business in New Yo |
|
| March 29, 2024 |
Kennisgeving van deelname (te gebruiken door houders van aandelen of inschrijvingsrechten) Exhibit 99.12 Gewone en Buitengewone Algemene Vergaderingen van 30 april 2024 Annual and Extraordinary Shareholders’ Meetings of 30 April 2024 Kennisgeving van deelname (te gebruiken door houders van aandelen of inschrijvingsrechten) Notification of participation (to be used by holders of shares or subscription rights) De ondergetekende: The undersigned: (Naam en adres / Name and address) heeft ke |
|
| March 29, 2024 |
Exhibit 99.15 Remuneration Policy 2 WWW.GLPG.COM #PioneeringForPatients This revised Remuneration Policy (‘Remuneration Policy’) of Galapagos NV (‘Galapagos’) is established in accordance with Article 7:89/1 of the Belgian Code of Companies and Associations and the 2020 Belgian Code of Corporate Governance (‘2020 Code’) and is applicable to Galapagos’ non-executive Directors and Executive Committe |
|
| March 29, 2024 |
Exhibit 99.9 English translation for information purposes GALAPAGOS Limited Liability Company Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium Company number: 0466.460.429 RLE Antwerp (division Mechelen) Report of the Board of Directors in accordance with Article 7:199 of the Belgian Companies and Associations Code Dear shareholders, In accordance with the provisions of article 7:199 |
|
| March 28, 2024 |
Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Thad Huston, certify that: 1. I have reviewed this annual report on Form 20-F of Galapagos NV; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to |
|
| March 28, 2024 |
Exhibit 13.1 Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the annual report of Galapagos NV (the “Company”) on Form 20-F for the fiscal year ended December 31, 2023 as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), I, Stoffels IM |
|
| March 28, 2024 |
COMPENSATION RECOVERY POLICY Adopted as of September 19, 2023 Exhibit 97.1 COMPENSATION RECOVERY POLICY Adopted as of September 19, 2023 Galapagos NV, a limited liability company incorporated in Belgium (the “Company”), acting on its own behalf and on behalf of its subsidiaries with whom Executive Officers as defined below have entered into service agreements regarding their Executive Officer role, has adopted a Compensation Recovery Policy (this “Policy”) a |
|
| March 28, 2024 |
EXHIBIT 15.2 March 28, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7561 Dear Sirs/Madams: We have read Item 16F of Galapagos NV's Form 20-F dated March 28, 2024, and have the following comments: 1.We agree with the statements made in the first, third, fourth and fifth paragraphs. 2.We have no basis on which to agree or disagree with the statements made in the |
|
| March 28, 2024 |
Subscription Right Plan 2023 BE GALAPAGOS NV General Rules EXHIBIT 4.59 Free translation for information purposes only Subscription Right Plan 2023 BE GALAPAGOS NV General Rules Free translation for information purposes only Table of Contents 1 Basis and Purpose 3 2 Definitions 3 3 Subscription Rights 5 3.1 General 5 3.2 Number per Beneficiary 5 3.3 Transfer restrictions 5 3.4 Exercise Price 5 3.5 Administration of the Subscription Right Plan 6 3.6 Expira |
|
| March 28, 2024 |
Subscription Right Plan 2022 (A) GALAPAGOS NV General Rules Free translation for information purposes only Exhibit 4.47 Subscription Right Plan 2022 (A) GALAPAGOS NV General Rules Free translation for information purposes only Table of Contents 1 Basis and Purpose3 2 Definitions3 3 Subscription Rights4 3.1 General4 3.2 Number per Beneficiary4 3.3 Transfer restrictions5 3.4 Exercise Price5 3.5 Administration of the Subscription Right Plan5 4 Ben |
|
| March 28, 2024 |
Exhibit 2.3 DESCRIPTION OF SECURITIES The following description of the securities registered under Section 12 of the Securities Exchange Act of 1934 of Galapagos NV (“Galapagos,” “us,” “our,” “we” or the “Company”) is a summary of the rights of our ordinary shares and certain provisions of our articles of association in effect as of March 20, 2023. This summary does not purport to be complete and |
|
| March 28, 2024 |
Subscription Right Plan 2023 RMV GALAPAGOS NV General Rules Free translation for information purposes only Exhibit 4.60 Subscription Right Plan 2023 RMV GALAPAGOS NV General Rules Free translation for information purposes only Table of Contents 1 Basis and Purpose 4 2 Definitions 4 3 Subscription Rights 6 3.1 General 6 3.2 Number per Beneficiary 6 3.3 Transfer restrictions 6 3.4 Exercise Price 6 3.5 Administration of the Subscription Right Plan 6 3.6 Expir |
|
| March 28, 2024 |
Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Stoffels IMC BV, permanently represented by Dr. Paul Stoffels, certify that: 1. I have reviewed this annual report on Form 20-F of Galapagos NV; 2. Based on my knowledge, this report does not contain |
|
| March 28, 2024 |
Restricted Stock Units/Long-Term Incentive Plan 2023 – Participants’ Guide EXHIBIT 4.57 Confidential RSU/LTIP 2023 Restricted Stock Units/Long-Term Incentive Plan 2023 – Participants’ Guide This multi-year Plan is intended to provide certain members of the Executive Committee and certain employees of Galapagos or its Affiliates the opportunity to receive Restricted Stock Units as a long-term incentive. Its purpose is to retain and encourage Participants to contribute to |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
|
| March 28, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement Nos. 333-268756, 333-260500, 333-249416, 333-231765, 333-225263, 333-218160, 333-215783, 333-211834, 333-208697, 333-204567 and 333-275886 on Form S-8 of our report dated March 23, 2023 (March 28, 2024 as to the effects of the discontinued operations describe |
|
| March 28, 2024 |
Restricted Stock Units/Retention Plan 2023 – Participants’ Guide Exhibit 4.58 Confidential RSU/Retention 2023 Restricted Stock Units/Retention Plan 2023 – Participants’ Guide This multi-year Plan is intended to provide certain members of the Executive Committee and certain employees of Galapagos or its Affiliates the opportunity to receive Restricted Stock Units as a long-term incentive. Its purpose is to retain and encourage Participants to contribute to the p |
|
| March 28, 2024 |
Consent of Independent Registered Public Accounting Firm EXHIBIT 15.3 Consent of Independent Registered Public Accounting Firm We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-204567, 333-208697, 333-211834, 333-215783, 333-218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756 and 333-275886) of Galapagos NV of our reports dated March 28, 2024, relating to the consolidated financial sta |
|
| March 28, 2024 |
Exhibit 13.2 Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the annual report of Galapagos NV (the “Company”) on Form 20-F for the fiscal year ended December 31, 2023 as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), I, Thad Huston |
|
| March 28, 2024 |
Subscription Right Plan 2023 ROW GALAPAGOS NV General Rules Free translation for information purposes only Exhibit 4.61 Subscription Right Plan 2023 ROW GALAPAGOS NV General Rules Free translation for information purposes only Table of Contents 1 Basis and Purpose 4 2 Definitions 4 3 Subscription Rights 6 3.1 General 6 3.2 Number per Beneficiary 6 3.3 Transfer restrictions 6 3.4 Exercise Price 6 3.5 Administration of the Subscription Right Plan 7 3.6 Expir |
|
| February 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive |
|
| February 23, 2024 |
Galapagos announces full year 2023 results and outlook for 2024 EXHIBIT 99.1 Galapagos announces full year 2023 results and outlook for 2024 Full year 2023 key financials: Group net revenues of €783.5 million, including Jyseleca® net sales of €112.3 million Cash and current financial investments of €3.7 billion on 31 December 2023 Operational cash burni of €414.8 million, within guidance 2023 and year-to-date key updates: Transferred Jyseleca® business, includ |
|
| February 16, 2024 |
Galapagos presents at EBMT-EHA annual meeting 2024 EXHIBIT 99.1 Galapagos presents at EBMT-EHA annual meeting 2024 Showcases meaningful advances in decentralized CAR T-cell manufacturing and presents translational and clinical data from ongoing Phase 1/2 CD19 CAR-T studies Mechelen, Belgium; 15 February 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) to present new preliminary translational data and previously disclosed data at the Europea |
|
| February 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive |
|
| February 14, 2024 |
GLPG / Galapagos NV - Depositary Receipt (Common Stock) / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Galapagos NV (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) 36315X1011 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| February 6, 2024 |
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma EXHIBIT 99.1 Galapagos completes transaction to transfer Jyseleca® business to Alfasigma Mechelen, Belgium; 31 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the successful completion of the transaction to transfer its Jyseleca® (filgotinib) business to Alfasigma S.p.A. As previously announced, the transfer includes the entire Jyseleca® business, including the Euro |
|
| February 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive o |
|
| January 5, 2024 |
EdgarFiling EXHIBIT 99.1 Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the U.S. Thermo Fisher Scientific to provide CAR-T manufacturing and kitting services for Galapagos’ point-of-care CAR-T product candidate in the San Francisco area Agreement follows previously announced collaboration with |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive o |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive o |
|
| January 4, 2024 |
Galapagos signs agreement to transfer Jyseleca® business to Alfasigma EdgarFiling EXHIBIT 99.1 Galapagos signs agreement to transfer Jyseleca® business to Alfasigma Transaction expected to close in the first quarter of 2024, subject to customary closing conditions Michele Manto, Galapagos’ Chief Commercial Officer, to join Alfasigma Mechelen, Belgium; 02 January 2024, 07:00 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and Alfasigma S.p.A. today announced that they ha |
|
| January 4, 2024 |
EXHIBIT 99.1 Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology Strategic collaboration and licensing agreement further strengthens Galapagos’ growing early-stage pipeline in oncology precision medicine Collaboration leverages Galapagos’ expertise in small molecule drug discovery and development with BridGene’s innovative dis |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive o |
|
| December 21, 2023 |
EXHIBIT 99.1 Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301 Mechelen, Belgium; 19 December 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient has been dosed in PAPILIO-1, the Phase 1/2 study to evaluate the safety, efficacy, and feasibility of our seven-day vein-to-vein |
|
| December 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive |
|
| December 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive |
|
| December 12, 2023 |
EXHIBIT 99.1 Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023 Mechelen, Belgium; 7 December 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will host a Key Opinion Leader (KOL) event during the 65th ASH Annual Meeting & Exposition in San Diego, CA, on Sunday, December 10, 2023, from 11:00 am PST to 12:30 pm |
|
| December 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive |
|
| December 12, 2023 |
EXHIBIT 99.1 Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101 Additional safety and efficacy data further support potential of innovative, decentralized approach to CAR-T manufacturing and transformational impact on patients with severe hematologic cancers Two poster presentations include recent data updates and additional data not incl |
|
| December 4, 2023 |
EX-4.1 Exhibit 4.1 Free translation from Dutch For information purposes only GALAPAGOS Limited Liability Company With office at Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium Judicial district of Mechelen (Belgium) Registered with the Register of Legal Entities under number 0466.460.429 www.glpg.com ********************* Coordination of the Articles of Association per 20 March 2023 ********* |
|
| December 4, 2023 |
Subscription Right Plan 2023 RMV GALAPAGOS NV General Rules Exhibit 99.3 Free translation for information purposes only Subscription Right Plan 2023 RMV GALAPAGOS NV General Rules Free translation for information purposes only Table of Contents 1 Basis and Purpose 4 2 Definitions 4 3 Subscription Rights 6 3.1 General 6 3.2 Number per Beneficiary 6 3.3 Transfer restrictions 6 3.4 Exercise Price 6 3.5 Administration of the Subscription Right Plan 6 3.6 Expir |
|
| December 4, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Galapagos NV (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title (1) Fee Calculation Rule (2) Amount Registered (3) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price (2) Fee Rate Amount of Registration Fee Equity Ordinary Shares, no par value Other 1,975,000 $39. |
|
| December 4, 2023 |
As filed with the U.S. Securities and Exchange Commission on December 4, 2023 As filed with the U.S. Securities and Exchange Commission on December 4, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GALAPAGOS NV (Exact name of registrant as specified in its charter) Belgium Not applicable (State or other jurisdiction of incorporation or organization) (I.R.S. E |
|
| December 4, 2023 |
Subscription Right Plan 2023 ROW GALAPAGOS NV General Rules EX-99.1 Exhibit 99.1 Free translation for information purposes only Subscription Right Plan 2023 ROW GALAPAGOS NV General Rules #126141734v1 - GLPG - Exhibit 99.1 to S-8 (Subscription Right Plan 2023 ROWEFINAL) Free translation for information purposes only Table of Contents 1 Basis and Purpose 3 2 Definitions 3 3 Subscription Rights 5 3.1 General 5 3.2 Number per Beneficiary 5 3.3 Transfer restri |
|
| December 4, 2023 |
Subscription Right Plan 2023 BE GALAPAGOS NV General Rules Exhibit 99.2 Free translation for information purposes only Subscription Right Plan 2023 BE GALAPAGOS NV General Rules Free translation for information purposes only Table of Contents 1 Basis and Purpose 3 2 Definitions 3 3 Subscription Rights 5 3.1 General 5 3.2 Number per Beneficiary 5 3.3 Transfer restrictions 5 3.4 Exercise Price 5 3.5 Administration of the Subscription Right Plan 6 3.6 Expira |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive |
|
| November 3, 2023 |
EXHIBIT 99.1 Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023 First nine months 2023 key financials: Group revenues of €448.9 million Jyseleca® net sales of €82.1 million Cash and current financial investments of €3.8 billion at 30 September 2023 Full year 2023 net Jyseleca® sales guidance of €100-€120 million and cash b |
|
| November 2, 2023 |
EXHIBIT 99.1 Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma Transaction would enable Galapagos to realize considerable annualized savings and accelerate its pipeline focused on developing transformational medicines Aims to preserve the Jyseleca® (filgotinib) business and a significant number of positions Galapagos plans to streamline |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive o |
|
| September 20, 2023 |
Galapagos appoints Simon Sturge to its Board of Directors EXHIBIT 99.1 Galapagos appoints Simon Sturge to its Board of Directors Mechelen, Belgium; 19 September 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that during its meeting of 19 September 2023, the Board of Directors appointed Mr. Simon Sturge as Non-Executive Independent Director by way of cooptation. Mr. Sturge replaces Dr. Mary Kerr who stepped down on 18 September 20 |
|
| September 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive |
|
| August 30, 2023 |
EdgarFiling EXHIBIT 99.1 Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus GLPG3667 is an investigational, novel, oral, reversible, and selective tyrosine kinase 2 (TYK2) inhibitor GLPG3667 is currently in development for the treatment of inflammatory and auto-immune diseases and is in Phase 2 for dermatomyositi |
|
| August 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive of |
|
| August 4, 2023 |
Half-year financial report 2023 Forward- with Purpose Pioneering for patients Exhibit 99.2 Half-year financial report 2023 Forward- with Purpose Pioneering for patients Table of Contents The Galapagos group A conversation with Paul and Thad 4 Key achievements 8 Financial highlights 14 Risk factors 18 The Galapagos share 19 Related party transactions 19 Disclaimer and other information 20 Financial statements Unaudited condensed consolidated interim financial statements 25 N |
|
| August 4, 2023 |
Galapagos announces first half-year 2023 financial results EX-99.1 Exhibit 99.1 Galapagos announces first half-year 2023 financial results • Half-year 2023 key financials • Group revenues of €328.8 million • Jyseleca® net sales of €54.3 million • Cash and current financial investments of €3.9 billion on 30 June 2023 • Full year 2023 net sales guidance for Jyseleca® lowered to €100-€120 million – 2023 cash burn guidance of €380-€420 million reiterated • On |
|
| August 4, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant’s name into English) Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium (Address of principal executi |
|
| June 15, 2023 |
Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer EdgarFiling EXHIBIT 99.1 Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer Mechelen, Belgium; 15 June 2023, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointment of Thad Huston as Chief Financial Officer (CFO) and Chief Operating Officer (COO) as per 1 July 2023. Mr. Huston will be a member of the Executive Com |
|
| June 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive offi |
|
| June 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive offi |
|
| June 13, 2023 |
Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board EdgarFiling EXHIBIT 99.1 Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board Mechelen, Belgium; 12 June 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that during its meeting of 12 June 2023, the Board of Directors co-opted Dr. Susanne Schaffert as non-executive independent Director. Dr. Schaffert replaces Dr. Rajesh Parekh who stepp |
|
| June 12, 2023 |
EdgarFiling EXHIBIT 99.1 Galapagos to showcase CAR-T point-of-care manufacturing and initial Phase 1/2 CLL data with CD19 CAR-T candidate, GLPG5201, at the EHA 2023 congress All 7 out of 7 eligible patients with relapsed/refractory chronic lymphocytic leukemia (rrCLL), with or without Richter’s Transformation (RT), responded to treatment (Objective Response Rate of 100%)1 GLPG5201 showed no cytoki |
|
| June 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive offi |
|
| June 7, 2023 |
GLPG / Galapagos NV - ADR / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Galapagos NV (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) 36315X1011 (CUSIP Number) June 7, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| May 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive offic |
|
| May 26, 2023 |
EdgarFiling EXHIBIT 99.1 Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with dermatomyositis GLPG3667 is an investigational, novel, oral, reversible, and selective tyrosine kinase 2 (TYK2) inhibitor GLPG3667 is currently in development for the treatment of inflammatory and auto-immune diseases and, if approved, has the potential to be the first sele |
|
| May 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive offic |
|
| May 23, 2023 |
Galapagos demonstrates commitment to immunology with new data in rheumatoid arthritis at EULAR 2023 EdgarFiling EXHIBIT 99.1 Galapagos demonstrates commitment to immunology with new data in rheumatoid arthritis at EULAR 2023 9 poster presentations and 3 abstracts publications reinforce Galapagos' commitment to immunology and the rheumatoid arthritis (RA) patient and healthcare professional community New analyses will be presented from long-term extension studies providing insights into filgotini |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive offic |
|
| May 9, 2023 |
Galapagos creates new subscription right plans EdgarFiling EXHIBIT 99.1 Galapagos creates new subscription right plans Mechelen, Belgium; 5 May 2023, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,975,000 subscription rights under new subscription right plans for the benefit of certain members of the personnel of the company and its subsidiaries. On 5 May 2023, th |
|
| May 5, 2023 |
Galapagos announces first quarter 2023 financial results EdgarFiling EXHIBIT 99.1 Galapagos announces first quarter 2023 financial results Progress with immunology and oncology pipeline: First patients dosed in pivotal Phase 3 OLINGUITO study with filgotinib in axial spondyloarthritis (AxSpA) Clinical sites opened to start patient recruitment in Phase 2 GALARISSO study with TYK2 inhibitor product candidate, GLPG3667, in dermatomyositis (DM) On track to |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive offic |
|
| May 2, 2023 |
Galapagos announces departure of Bart Filius, Chief Operating Officer and Chief Financial Officer EXHIBIT 99.1 Galapagos announces departure of Bart Filius, Chief Operating Officer and Chief Financial Officer Mechelen, Belgium; 2 May 2023, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced the departure of Bart Filius, President, Chief Operating Officer and Chief Financial Officer. Bart Filius joined Galapagos in 2014 as Chief Financial Officer and subseq |
|
| May 2, 2023 |
Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis EdgarFiling EXHIBIT 99.1 Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis OLINGUITO Phase 3 program in adults with axial spondyloarthritis (AxSpA) to include two parallel studies to investigate the efficacy and safety of filgotinib in patients with active radiographic AxSpA (r-AxSpA) and non-radiographic AxSpA (nr-AxSpA) Results from Phase 2 TORTU |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive off |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive offic |
|
| April 26, 2023 |
EdgarFiling EXHIBIT 99.1 Galapagos’ shareholders approve all resolutions proposed by the Board of Directors at the annual shareholders’ meeting Mechelen, Belgium; 25 April 2023, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announces the approval of all resolutions proposed at its annual shareholders’ meeting (AGM) held today at 14.00 CET. The AGM approved, amongst other items, the re-ap |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive off |
|
| April 25, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023. Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant’s name into English) Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium (Address of principal executi |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive off |
|
| March 31, 2023 |
Galapagos and NovAliX enter into an integrated drug discovery collaboration EdgarFiling EXHIBIT 99.1 Galapagos and NovAliX enter into an integrated drug discovery collaboration Galapagos to transfer drug discovery and research activities in Romainville, France to NovAliX, a drug-discovery focused Contract Research Organization (CRO) based in Strasbourg, France NovAliX to assume Galapagos’ research capabilities, and Galapagos retains flexibility to access necessary experti |
|
| March 27, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023. Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant’s name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executiv |
|
| March 27, 2023 |
Forward with Purpose Annual Report 2022 EX-99.2 Exhibit 99.2 Forward with Purpose Annual Report 2022 TABLE OF CONTENTS Table of Contents The Galapagos group Corporate governance Letter from the CEO and Chairman 4 Galapagos’ corporate governance policies 90 Our Company 7 Board of Directors of Galapagos NV 93 Key achievements in 2022 9 Committees 106 Potential external impacts 17 Executive Committee of Galapagos NV 109 Going concern state |
|
| March 27, 2023 |
EX-99.4 Exhibit 99.4 Free translation from Dutch For information purposes only GALAPAGOS NV Limited liability company Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium Company Number: 0466.460.429 RLE Antwerp - division Mechelen Invitation to the Annual Shareholders’ Meeting to be held on 25 April 2023 The Board of Directors of Galapagos NV (hereinafter the “Company”, or “Galapagos”) has the ho |
|
| March 27, 2023 |
EX-99.7 Exhibit 99.7 Galapagos NV Statutory auditor’s report to the shareholders’ meeting for the year ended 31 December 2022 – Annual accounts The original text of this report is in Dutch Galapagos NV | 31 December 2022 Statutory auditor’s report to the shareholders’ meeting of Galapagos NV for the year ended 31 December 2022—Annual accounts In the context of the statutory audit of the annual acc |
|
| March 27, 2023 |
EX-99.8 Exhibit 99.8 Time Sensitive Materials Depositary’s Notice of Annual Shareholders’ Meeting of Galapagos NV ADSs: American Depositary Shares (“ADSs”). ADS CUSIP No.: 36315X101. Company: Galapagos NV, a company organized and existing under the laws of the Kingdom of Belgium (the “Company”). ADS Record Date: March 17, 2023 (close of business in New York). Date used to determine ADS Holders who |
|
| March 27, 2023 |
EX-99.10 Exhibit 99.10 Gewone Algemene Vergadering van 25 april 2023 Annual Shareholders’ Meeting of 25 April 2023 Kennisgeving van deelname (enkel te gebruiken door houders van aandelen op naam of inschrijvingsrechten) Notification of participation (to be used by holders of registered shares or subscription rights only) De ondergetekende: The undersigned: (Naam en adres / Name and address) heeft |
|
| March 27, 2023 |
Volmacht (enkel te gebruiken door aandeelhouders) EX-99.5 Exhibit 99.5 Gewone Algemene Vergadering van 25 april 2023 Annual Shareholders’ Meeting of 25 April 2023 Volmacht (enkel te gebruiken door aandeelhouders) Proxy (to be used by shareholders only) De ondergetekende: The undersigned: (Naam en adres / Name and address) hierin optredend als lastgever, eigenaar van het volgende aantal aandelen in Galapagos NV (naamloze vennootschap naar Belgisch |
|
| March 27, 2023 |
EX-99.11 Exhibit 99.11 GALAPAGOS NV Naamloze vennootschap / Limited liability company Generaal De Wittelaan L11 A3, 2800 Mechelen, België / Belgium ondernemingsnummer / company number 0466.460.429 RPR Antwerpen, afdeling Mechelen / RLE Antwerp, division Mechelen Op 23 maart 2023 bedraagt het totaal aantal aandelen en stemrechten van Galapagos NV 65.897.071 On 23 March 2023, the total number of sha |
|
| March 27, 2023 |
EX-99.9 Exhibit 99.9 Annual Shareholders’ Meeting The Voting Instructions must be signed, completed and received at the indicated address prior to 10:00 A.M. (New York City time) on April 17, 2023 for action to be taken. 2023 VOTING INSTRUCTIONS AMERICAN DEPOSITARY SHARES Galapagos NV (the “Company”) ADS CUSIP No.: 36315X101. ADS Record Date: March 17, 2023 (close of business in New York). Share R |
|
| March 27, 2023 |
Stemmen per brief (enkel te gebruiken door aandeelhouders) EX-99.12 Exhibit 99.12 Gewone Algemene Vergadering van 25 april 2023 Annual Shareholders’ Meeting of 25 April 2023 Stemmen per brief (enkel te gebruiken door aandeelhouders) Voting by letter (to be used by shareholders only) De ondergetekende: The undersigned: (Naam en adres / Name and address) eigenaar van het volgende aantal aandelen in Galapagos NV (naamloze vennootschap naar Belgisch recht, me |
|
| March 27, 2023 |
EX-99.3 Exhibit 99.3 23 March 2023 Subject: Galapagos AGM 2023 Dear shareholders and holders of subscription rights, In 2022, Galapagos (the “Company”) embarked on a new chapter under the leadership of Dr. Paul Stoffels*, who was appointed as CEO, effective 1 April 2022. As approved at our Shareholders’ Meetings in April 2022, we implemented a one-tier governance structure and Dr. Paul Stoffels wa |
|
| March 27, 2023 |
EX-99.6 Exhibit 99.6 Free translation from original Dutch filed version for information purposes only F-cap 1 ANNUAL ACCOUNTS AND OTHER DOCUMENTS TO BE FILED IN ACCORDANCE WITH THE BELGIAN COMPANIES AND ASSOCIATIONS CODE IDENTIFICATION DETAILS (at the filing date) NAME: Galapagos Legal form 1 : Public limited company Address: Generaal De Wittelaan Postal code: 2800 Town: Mechelen N°. L11 , box A3 |
|
| March 27, 2023 |
Galapagos publishes 2022 annual report and announces Annual Shareholders’ Meeting EX-99.1 Exhibit 99.1 Galapagos publishes 2022 annual report and announces Annual Shareholders’ Meeting • Publication of annual report for financial year 2022 • Annual Shareholders’ Meeting proposed resolutions include re-appointment of Board members and appointment of new statutory auditor Mechelen, Belgium; 23 March 2023, 21.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) t |
|
| March 23, 2023 |
Addendum to the Lease Agreement Intervest Offices & Warehouses NV - Galapagos NV Exhibit 4. |
|
| March 23, 2023 |
Subscription Right Plan 2022 (B) (English translation) Free translation for information purposes only Exhibit 4.48 Subscription Right Plan 2022 (B) GALAPAGOS NV General Rules Free translation for information purposes only Table of Contents 1Basis and Purpose3 2Definitions3 3Subscription Rights4 3.1General4 3.2Number per Beneficiary5 3.3Transfer restrictions5 3.4Exercise Price5 3.5Administration of the Subscription Right Plan5 4Beneficiarie |
|
| March 23, 2023 |
Exhibit 13.1 Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the annual report of Galapagos NV (the “Company”) on Form 20-F for the fiscal year ended December 31, 2022 as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), I, Stoffels IM |
|
| March 23, 2023 |
Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Stoffels IMC BV, permanently represented by Dr. Paul Stoffels, certify that: 1. I have reviewed this annual report on Form 20-F of Galapagos NV; 2. Based on my knowledge, this report does not contain |
|
| March 23, 2023 |
Plan 2022.III – RSU GSI Replacement Plan 2022 (English translation) EX-4.54 8 glpg-20221231xex4d54.htm EX-4.54 Confidential GSI RSU 2022 Exhibit 4.54 Restricted Stock Units GSI Replacement Plan 2022 – Participants’ Guide This Plan is intended to compensate employees who transferred from Gilead Sciences, Inc (“GSI”) to Galapagos (in the framework of Project Butterfly) for the long-term incentive plans within Gilead under which unvested RSU awards lapse upon transfe |
|
| March 23, 2023 |
Exhibit 13.2 Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the annual report of Galapagos NV (the “Company”) on Form 20-F for the fiscal year ended December 31, 2022 as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), I, Bart Filius |
|
| March 23, 2023 |
Galapagos increases share capital through subscription right exercises EdgarFiling EXHIBIT 99.1 Galapagos increases share capital through subscription right exercises Mechelen, Belgium; 20 March 2023, 21.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises. Galapagos issued 61,560 new ordinary shares on 20 March 2023, for a total capital increase (including issuance premium |
|
| March 23, 2023 |
Plan 2022.II – RSU Retention Plan 2022 (English translation) Confidential RSU/Retention 2022 Exhibit 4.53 Restricted Stock Units/Retention Plan 2022 – Participants’ Guide This multi-year Plan is intended to provide certain members of the executive committee and certain employees of Galapagos the opportunity to receive Restricted Stock Units as a long-term incentive. Its purpose is to retain and encourage Participants to contribute to the performance of Gala |
|
| March 23, 2023 |
Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Bart Filius, certify that: 1. I have reviewed this annual report on Form 20-F of Galapagos NV; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
|
| March 23, 2023 |
Exhibit 2.3 DESCRIPTION OF SECURITIES The following description of the securities registered under Section 12 of the Securities Exchange Act of 1934 of Galapagos NV (“Galapagos,” “us,” “our,” “we” or the “Company”) is a summary of the rights of our ordinary shares and certain provisions of our Articles of Association in effect as of March 20, 2023. This summary does not purport to be complete and |
|
| March 23, 2023 |
Articles of Association (English translation), as amended Exhibit 1.1 Free translation from Dutch For information purposes only GALAPAGOS Limited Liability Company With office at Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium Judicial district of Mechelen (Belgium) Registered with the Register of Legal Entities under number 0466.460.429 www.glpg.com ********************* Coordination of the Articles of Association per 20 March 2023 **************** |
|
| March 23, 2023 |
6-K 1 f6k032323.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Addre |
|
| March 23, 2023 |
Addendum to the Lease Agreement Intervest Offices & Warehouses NV - Galapagos NV Exhibit 4. |
|
| March 23, 2023 |
Plan 2022.I – RSU Long-Term Incentive Plan 2022 (English translation) Confidential RSU/LTIP 2022 Exhibit 4.52 Restricted Stock Units/Long-Term Incentive Plan 2022 – Participants’ Guide This multi-year Plan is intended to provide certain members of the executive committee and certain employees of Galapagos the opportunity to receive Restricted Stock Units as a long-term incentive. Its purpose is to retain and encourage Participants to contribute to the performance of |
|
| March 23, 2023 |
Subscription Right Plan 2022 (A) (English translation) Free translation for information purposes only Exhibit 4.47 Subscription Right Plan 2022 (A) GALAPAGOS NV General Rules Free translation for information purposes only Table of Contents 1 Basis and Purpose3 2 Definitions3 3 Subscription Rights4 3.1 General4 3.2 Number per Beneficiary4 3.3 Transfer restrictions5 3.4 Exercise Price5 3.5 Administration of the Subscription Right Plan5 4 Ben |
|
| March 23, 2023 |
Consent of Deloitte Bedrijfsrevisoren Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference into the Company’s Registration Statement on Form S-8 Nos. 333-268756, 333-260500, 333-249416, 333-231765, 333-225263, 333-218160, 333-215783, 333-211834, 333-208697, 333-204567 of our reports dated March 23, 2023, relating to the financial statements of Galapagos NV and the effective |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive |
|
| February 28, 2023 |
EdgarFiling EXHIBIT 99.1 Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023 Six presentations demonstrate Galapagos’ commitment to the inflammatory bowel disease (IBD) community New analyses from Phase 3 SELECTION and SELECTION long-term extension (LTE) studies of Jyseleca® (filgotinib, an oral, once daily, JAK1 preferentia |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File Number: 001-37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive |
|
| February 24, 2023 |
Galapagos announces full year 2022 results and outlook for 2023 EdgarFiling EXHIBIT 99.1 Galapagos announces full year 2022 results and outlook for 2023 Key 2022 and post-period events Dr. Paul Stoffelsi appointed as Chief Executive Officer and Chairman of the Board of Directors Implemented new strategic direction to accelerate innovation and time-to-patients: Set-up of new innovation model and fit-for-purpose R&D organization Focus on key therapeutic areas of |
|
| February 14, 2023 |
GLPG / Galapagos N.V. / EcoR1 Capital, LLC Passive Investment SC 13G/A 1 galapagos13ga1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Galapagos NV (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) 36315X1011 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
